GD2-Targeting CAR with Suicide Gene Safety Switch
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for neuroblastoma and other GD2-expressing cancers, such as those using anti-GD2 antibodies, have limited efficacy in eradicating bulky disease and are associated with significant toxicity, necessitating the development of more effective and less toxic treatments.
Innovation Solution
A new chimeric antigen receptor (CAR) targeting GD2, comprising a GD2-binding domain based on the KM666 antibody, with a humanized scFv format and optimized spacer and signaling domains, is developed to enhance T-cell activation and killing efficiency, and is co-expressed with suicide genes for safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-GD2 antibodies are used for therapy, then some therapeutic effect is achieved, but neurotoxicity and limited efficacy against bulky disease occur
Solution Approach 1:
The patent segments the therapeutic approach by using CAR-T cells that specifically recognize GD2 on tumor cells while sparing normal GD2-expressing tissues through controlled activation mechanisms and suicide gene switches, thereby separating therapeutic effect from toxic effects
Solution Approach 2:
The patent changes the activation parameters of the immune response by using CAR-T cells that require specific activation conditions (antigen binding plus co-stimulation) to differentiate between tumor cells and normal tissues, reducing neurotoxicity while maintaining efficacy
2Reliability
If existing CARs are used to target GD2, then T-cell activation is achieved, but killing efficiency against GD2-positive cells is insufficient
Solution Approach 1:
The patent merges multiple functional domains into a single CAR construct including antigen recognition (scFv), co-stimulation (CD28, OX40), and signaling (CD3ζ) domains, creating a unified receptor that simultaneously achieves strong T-cell activation and efficient killing of GD2-positive cells
3Productivity
If therapeutic intensity is increased to improve efficacy, then killing efficiency improves, but toxicity increases
Solution Approach 1:
The patent incorporates suicide genes (iCasp9, RQR8) that provide feedback control by allowing selective deletion of CAR-T cells when toxicity occurs, enabling high killing efficiency while maintaining safety through controllable termination of the therapeutic agent
Solution Approach 2:
The patent creates a dynamic therapeutic system where CAR-T cell activity can be modulated and terminated on demand through suicide gene activation, allowing the system to adapt between high efficacy and low toxicity states as needed
Data Source
AI summary
Provision of a chimeric antigen receptor (CAR) comprising a disialoganglioside (GD2)-binding domain which comprises⋅a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences:⋅b) a light chain variable region (VL) having CDRs with the following sequences: T cells expressing such a CAR are useful in the treatment of some cancers.